Ligandrol (LGD-4033)
Potent oral SARM with significant lean mass effects in Phase I trials
Mechanism of Action
Ligandrol (LGD-4033, VK5211) is a potent non-steroidal oral SARM that binds the androgen receptor with high affinity (Ki ~1 nM) and demonstrates marked tissue selectivity. In a Phase I multiple ascending dose study, LGD-4033 produced dose-dependent increases in lean body mass (up to 2.67 lbs at 1.0 mg/day) with improvements in physical function. The compound does not aromatize to estrogen and is not a substrate for 5-alpha reductase. LGD-4033 shows minimal effect on prostate-specific antigen (PSA) and hematocrit at therapeutic doses, distinguishing it from traditional AAS.
Evidence Chain
Ligandrol (LGD-4033)
COMPOUND
1 Research Goal
• Muscle & Tissue Growth
Evidence Strength
7 articles sourced
Knowledge Graph
(8 connections)Research Evidence
(7)Ligandrol (LGD-4033): Evidence-Based Research Review
Ligandrol (LGD-4033), also known as VK5211, is a potent, non-steroidal selective androgen receptor modulator (SARM) developed for the treatment of conditions characterized by muscle wasting and osteoporosis. As a SARM, it is designed to exert anabolic effects on skeletal muscle and bone while minimi
Enobosarm (Ostarine / MK-2866): Evidence-Based Research Review
**Class:** SARM (Selective Androgen Receptor Modulator)
Ligandrol vs RAD-140: Evidence-Based Comparison
Selective Androgen Receptor Modulators (SARMs) were developed to provide the therapeutic benefits of androgen replacement therapy—such as increased muscle mass and bone density—while minimizing the adverse effects associated with conventional anabolic-androgenic steroids (AAS), specifically prostate
Ostarine vs Ligandrol: Evidence-Based Comparison
Selective Androgen Receptor Modulators (SARMs) represent a class of therapeutic compounds designed to elicit the anabolic benefits of traditional androgenic anabolic steroids (AAS) while minimizing adverse effects on non-target tissues (e.g., prostate and sebaceous glands). Enobosarm (Ostarine/MK-28
YK-11: Evidence-Based Research Review
YK-11 (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester is a synthetic compound classified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional non-steroidal SARMs such as Ostarine or Ligandrol, YK-11 possesses a steroidal
Testolone (RAD-140): Evidence-Based Research Review
Testolone (RAD-140) is a potent, non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. It was designed to overcome the limitations of conventional androgen therapy, such as prostate enlargement and virilization, by exhibiting high tissue selectivity.
Andarine (S-4): Evidence-Based Research Review
Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Highest Compatibility
Ligandrol (LGD-4033) + Enobosarm (Ostarine / MK-2866)
High Compatibility
Shared targets: androgen receptor (ar) — tissue-selective
Shared targets: androgen receptor (ar) — tissue-selective
Shared targets: androgen receptor (ar) — tissue-selective
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.